Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Authorized Generics for Iressa, Urief to Join NHI Price List; Nesp Biosame Skips Listing
The Ministry of Health, Labor and Welfare (MHLW) will add a raft of generics to the NHI price list on December 14, including authorized generic (AG) versions of AstraZeneca’s cancer drug Iressa (gefitinib) and Kissei Pharmaceutical’s dysuria treatment Urief (silodosin).…
To read the full story
Related Article
- Nesp Biosame to Hit Japan Market in July-September 2019
October 31, 2018
- Kyowa Kirin Mum on Listing Request Status for Nesp “Biosame”
August 24, 2018
- Daiichi Sankyo Espha Unveils Authorized Generic Pact with AstraZeneca, 3 More Oncology AGs Pending Approval
August 21, 2018
- Nesp “Biosame” Could Hit Market as Early as December
August 17, 2018
- Daiichi Sankyo Espha Likely to Roll Out Urief, Iressa Authorized Generics: December Listing
August 16, 2018
- Japan Approves Nesp “Biosame,” Eyes Riveted on December Listing
August 16, 2018
REGULATORY
- Council Floats 9.6% Growth Target for Japan’s On-Patent Drug Market
March 11, 2026
- MHLW Approves Towa Generics for Revolade, Vimpat
March 11, 2026
- Panel Clears Zolgensma Intrathecal Form to Expand Use in Older SMA Patients
March 10, 2026
- Japan Approves MSD’s HIV Combo Idvynso
March 9, 2026
- MHLW Updates Elective Care LLP List; Target Products Down Sharply to 776
March 9, 2026
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…